Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: Understanding different clinical responses to immunotherapy

Expert Review of Vaccines

Volumn 11, Issue 7, 2012, Pages 821-840

  Van Esch, Edith M ^a   Welters, Marij J ^a   Jordanova, Ekaterina S ^a   Trimbos, J Baptist M ^a   Van Der Burg, Sjoerd H ^a   Van Poelgeest, Mariëtte I ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

HPV; immune escape; immune modulation; immunotherapy; macrophages; Tregs; vaccination; VIN

Indexed keywords

ALPHA INTERFERON; AMINOLEVULINIC ACID; IMIQUIMOD; PEPTIDE VACCINE; WART VIRUS VACCINE;

CANCER IMMUNOTHERAPY; CELLULAR IMMUNITY; DISEASE ASSOCIATION; DRUG TREATMENT FAILURE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; IMMUNE SYSTEM; IMMUNOGENETICS; INNATE IMMUNITY; LYMPHOCYTIC INFILTRATION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; UTERINE CERVIX TUMOR; VAGINAL INTRAEPITHELIAL NEOPLASIA; VULVA TUMOR;

ANIMALS; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RISK FACTORS; TREATMENT FAILURE; UTERINE CERVICAL NEOPLASMS;

EID: 84865442029     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.56     Document Type: Review

References (196)

1. van de Nieuwenhof HP, van der Avoort IA, de Hullu JA. Review of squamous premalignant vulvar lesions. Crit. Rev. Oncol. Hematol. 68(2), 131-156 (2008).
2. Sideri M, Jones RW, Wilkinson EJ et al. Squamous vulvar intraepithelial neoplasia: 2004 modified terminology, ISSVD Vulvar Oncology Subcommittee. J. Reprod. Med. 50(11), 807-810 (2005). (Pubitemid 41720964)
3. van de Nieuwenhof HP, Massuger LF, van der Avoort IA, Bekkers RL, Casparie M, Abma W et al. Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. Eur. J. Cancer 45(5), 851-856 (2009).
4. Garland SM, Insinga RP, Sings HL, Haupt RM, Joura EA. Human papillomavirus infections and vulvar disease development. Cancer Epidemiol. Biomarkers Prev. 18(6), 1777-1784 (2009).
5. De Vuyst H, Clifford GM, Nascimento MC, Madeleine MM, Franceschi S. Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta-analysis. Int. J. Cancer 124(7), 1626-1636 (2009).
6. Joura EA, Lösch A, Haider-Angeler MG, Breitenecker G, Leodolter S. Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. J. Reprod. Med. 45(8), 613-615 (2000). (Pubitemid 30661117)
7. Judson PL, Habermann EB, Baxter NN, Durham SB, Virnig BA. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet. Gynecol. 107(5), 1018-1022 (2006).
8. Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J. Clin. Virol. 32(Suppl. 1), S16-S24 (2005). (Pubitemid 40332585)
9. Koutsky L. Epidemiology of genital human papillomavirus infection. Am. J. Med. 102(5A), 3-8 (1997). (Pubitemid 127695953)
10. van Seters M, van Beurden M, de Craen AJ. Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. Gynecol. Oncol. 97(2), 645-651 (2005). (Pubitemid 40614916)
11. Jones RW, Rowan DM, Stewart AW. Vulvar intraepithelial neoplasia: Aspects of the natural history and outcome in 405 women. Obstet. Gynecol. 106(6), 1319-1326 (2005). (Pubitemid 41668952)
12. Hillemanns P, Wang X, Staehle S, Michels W, Dannecker C. Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy. Gynecol. Oncol. 100(2), 271-275 (2006). (Pubitemid 43075260)
13. Kaushik S, Pepas L, Nordin A, Bryant A, Dickinson HO. Surgical interventions for high grade vulval intraepithelial neoplasia. Cochrane Database Syst. Rev. (1), CD007928 (2011).
14. Aerts L, Enzlin P, Vergote I, Verhaeghe J, Poppe W, Amant F. Sexual, psychological, and relational functioning in women after surgical treatment for vulvar malignancy: A literature review. J. Sex. Med. 9(2), 361-371 (2012).
15. Doorbar J. The papillomavirus life cycle. J. Clin. Virol. 32(Suppl. 1), S7-S15 (2005). (Pubitemid 40332584)
16. zur Hausen H. Papillomavirus infections-a major cause of human cancers. Biochim. Biophys. Acta 1288(2), F55-F78 (1996). (Pubitemid 26335492)
17. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338(7), 423-428 (1998). (Pubitemid 28135669)
18. Brown DR, Shew ML, Qadadri B et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J. Infect. Dis. 191(2), 182-192 (2005). (Pubitemid 40096375)
19. Sellors JW, Karwalajtys TL, Kaczorowski J et al.; Survey of HPV in Ontario Women Group. Incidence, clearance and predictors of human papillomavirus infection in women. CMAJ 168(4), 421-425 (2003). (Pubitemid 36255727)
20. Insinga RP, Perez G, Wheeler CM et al.; FUTURE I Investigators. Incidence, duration, and reappearance of type-specific cervical human papillomavirus infections in young women. Cancer Epidemiol. Biomarkers Prev. 19(6), 1585-1594 (2010). Demonstrates the incidence and duration of cervical HPV infection episodes in 1788 women aged 16-23 years at 6-month intervals for up to 4 years along with the risk of reappearance following a period of nondetection.
21. Goffin F, Mayrand MH, Gauthier P et al. High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia. J. Med. Virol. 78(6), 814-819 (2006).
22. Vinokurova S, Wentzensen N, Einenkel J et al. Clonal history of papillomavirusinduced dysplasia in the female lower genital tract. J. Natl Cancer Inst. 97(24), 1816-1821 (2005). (Pubitemid 43033902)
23. Kjellberg L, Hallmans G, Ahren AM et al. Smoking, diet, pregnancy and oral contraceptive use as risk factors for cervical intra-epithelial neoplasia in relation to human papillomavirus infection. Br. J. Cancer 82(7), 1332-1338 (2000). (Pubitemid 30145354)
24. Khan AM, Freeman-Wang T, Pisal N, Singer A. Smoking and multicentric vulval intraepithelial neoplasia. J. Obstet. Gynaecol. 29(2), 123-125 (2009).
25. Zur Hausen H. Papillomaviruses and cancer: From basic studies to clinical application. Nat. Rev. Cancer 2(5), 342-350 (2002). (Pubitemid 37328947)
26. Kanodia S, Fahey LM, Kast WM. Mechanisms used by human papillomaviruses to escape the host immune response. Curr. Cancer Drug Targets 7(1), 79-89 (2007). (Pubitemid 46345510)
27. Hegde RS. The papillomavirus E2 proteins: Structure, function, and biology. Annu. Rev. Biophys. Biomol. Struct. 31, 343-360 (2002). (Pubitemid 34666837)
28. van Seters M, van Beurden M, ten Kate FJ et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N. Engl. J. Med. 358(14), 1465-1473 (2008). A randomized clinical trial with topical imiquimod for the treatment of vulvar intraepithelial neoplasia (VIN). Treatment with imiquimod compared with placebo achieved a complete response in 35% and overall clinical response in 81% of patients. (Pubitemid 351482738)
29. Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361(19), 1838-1847 (2009). Shows the immunogenicity and efficacy of synthetic long peptides vaccination in patients with HPV16+ VIN 3 lesions and the correlation overall between immunological parameters and clinical success.
30. Winters U, Daayana S, Lear JT et al. Clinical and immunologic results of a Phase II trial of sequential imiquimod and photodynamic therapy for vulval intraepithelial neoplasia. Clin. Cancer Res. 14(16), 5292-5299 (2008). High-grade VIN treated with imiquimod and sequentially photodynamic therapy (PDT) results in 64% overall response rate whereas the nonresponsiveness was associated with a significantly higher level of intralesional Tregs after imiquimod.
31. Daayana S, Elkord E, Winters U et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br. J. Cancer 102(7), 1129-1136 (2010). Topical imiquimod for 8 weeks followed by three TA-CIN vaccinations results in 63% complete regression of VIN lesions after 52 weeks and is correlated with increased systemic proliferation to HPV antigens and local infiltration of CD8+ and CD4+ intralesional T cells.
32. Mathiesen O, Buus SK, Cramers M. Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double-blinded study. Gynecol. Oncol. 107(2), 219-222 (2007). (Pubitemid 47575715)
33. Terlou A, van Seters M, Ewing PC et al. Treatment of vulvar intraepithelial neoplasia with topical imiquimod: Seven years median follow-up of a randomized clinical trial. Gynecol. Oncol. 121(1), 157-162 (2011).
34. Richardson H, Kelsall G, Tellier P et al. The natural history of type-specific human papillomavirus infections in female university students. Cancer Epidemiol. Biomarkers Prev. 12(6), 485-490 (2003). (Pubitemid 36713640)
35. Bowie AG, Unterholzner L. Viral evasion and subversion of pattern-recognition receptor signalling. Nat. Rev. Immunol. 8(12), 911-922 (2008).
36. Takeuchi O, Akira S. Innate immunity to virus infection. Immunol. Rev. 227(1), 75-86 (2009).
37. Kalali BN, Köllisch G, Mages J et al. Double-stranded RNA induces an antiviral defense status in epidermal keratinocytes through TLR3-, PKR-, and MDA5/ RIG-I-mediated differential signaling. J. Immunol. 181(4), 2694-2704 (2008).
38. Karim R, Meyers C, Backendorf C et al. Human papillomavirus deregulates the response of a cellular network comprising of chemotactic and proinflammatory genes. PLoS ONE 6(3), e17848 (2011). Shows dampening in regulation of signaling of pathogen recognition receptors by HPV. Many of the genes downregulated in HPV positive keratinocytes are involved in components of the antigen-presenting pathway, the inflammasome, the production of antivirals, proinflammatory and chemotactic cytokines and components of downstream of activated pathogen recognition receptors.
39. Lebre MC, van der Aar AM, van Baarsen L et al. Human keratinocytes express functional Toll-like receptor 3, 4, 5, and 9. J. Invest. Dermatol. 127(2), 331-341 (2007). (Pubitemid 46106911)
40. Andersen JM, Al-Khairy D, Ingalls RR. Innate immunity at the mucosal surface: Role of toll-like receptor 3 and Toll-like receptor 9 in cervical epithelial cell responses to microbial pathogens. Biol. Reprod. 74(5), 824-831 (2006).
41. Zijlmans HJ, Fleuren GJ, Baelde HJ, Eilers PH, Kenter GG, Gorter A. Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen presenting cells in cervical carcinoma. Cancer 109(3), 556-565 (2007). (Pubitemid 46190964)
42. Jakob T, Ring J, Udey MC. Multistep navigation of Langerhans/dendritic cells in and out of the skin. J. Allergy Clin. Immunol. 108(5), 688-696 (2001). (Pubitemid 33096196)
43. Petry KU, Köchel H, Bode U et al. Human papillomavirus is associated with the frequent detection of warty and basaloid high-grade neoplasia of the vulva and cervical neoplasia among immunocompromised women. Gynecol. Oncol. 60(1), 30-34 (1996). (Pubitemid 26028453)
44. Jamieson DJ, Paramsothy P, Cu-Uvin S, Duerr A; HIV Epidemiology Research Study Group. Vulvar, vaginal, and perianal intraepithelial neoplasia in women with or at risk for human immunodeficiency virus. Obstet. Gynecol. 107(5), 1023-1028 (2006).
45. Woo YL, van den Hende M, Sterling JC et al. A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6-and E7-specific T-cell responses. Int. J. Cancer 126(1), 133-141 (2010). Large prospective study of 125 women that show that the majority of low grade squamous intraepithelial lesions persisted or progressed within the first year, paralleled by immune failure as most of the patients with an HPV16+ low grade squamous intraepithelial lesions failed to react to HPV16 E2, E6 or E7.
46. van der Burg SH, Palefsky JM. Human immunodeficiency virus and human papilloma virus-why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful. J. Transl. Med. 7, 108 (2009).
47. Kalinski P, Hilkens CM, Wierenga EA, Kapsenberg ML. T-cell priming by type-1 and type-2 polarized dendritic cells: The concept of a third signal. Immunol. Today 20(12), 561-567 (1999).
48. Wang HY, Lee DA, Peng G et al. Tumorspecific human CD4+ regulatory T cells and their ligands: Implications for immunotherapy. Immunity 20(1), 107-118 (2004). (Pubitemid 38134298)
49. Coleman N, Birley HD, Renton AM et al. Immunological events in regressing genital warts. Am. J. Clin. Pathol. 102(6), 768-774 (1994).
50. de Jong A, van der Burg SH, Kwappenberg KM et al. Frequent detection of human papillomavirus 16 E2-specific T-helper immunity in healthy subjects. Cancer Res. 62(2), 472-479 (2002). (Pubitemid 34106421)
51. Welters MJ, de Jong A, van den Eeden SJ et al. Frequent display of human papillomavirus type 16 E6-specific memory T-helper cells in the healthy population as witness of previous viral encounter. Cancer Res. 63(3), 636-641 (2003). (Pubitemid 36158141)
52. Woo YL, Sterling J, Damay I et al. Characterising the local immune responses in cervical intraepithelial neoplasia: A cross-sectional and longitudinal analysis. BJOG 115(13), 1616-1621; discussion 1621 (2008).
53. Farhat S, Nakagawa M, Moscicki AB. Cell-mediated immune responses to human papillomavirus 16 E6 and E7 antigens as measured by interferon gamma enzymelinked immunospot in women with cleared or persistent human papillomavirus infection. Int. J. Gynecol. Cancer 19(4), 508-512 (2009). Shows the critical role of E6-and E7-specific IFN-γ-associated T-cell responses in the clearance and persistence of HPV16 infection.
54. Bourgault Villada I, Moyal Barracco M, Villada IB et al. Spontaneous regression of grade 3 vulvar intraepithelial neoplasia associated with human papillomavirus-16-specific CD4(+) and CD8(+) T-cell responses. Cancer Res. 64(23), 8761-8766 (2004). (Pubitemid 39552094)
55. van Poelgeest MI, Nijhuis ER, Kwappenberg KM et al. Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. Int. J. Cancer 118(3), 675-683 (2006). (Pubitemid 43076017)
56. de Jong A, van Poelgeest MI, van der Hulst JM et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res. 64(15), 5449-5455 (2004). (Pubitemid 39006568)
57. Nakagawa M, Stites DP, Farhat S et al. Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: Relationship to cervical intraepithelial neoplasia. J. Infect. Dis. 175(4), 927-931 (1997). (Pubitemid 27142969)
58. de Vos van Steenwijk PJ, Piersma SJ, Welters MJ et al. Surgery followed by persistence of high-grade squamous intraepithelial lesions is associated with the induction of a dysfunctional HPV16-specific T-cell response. Clin. Cancer Res. 14(22), 7188-7195 (2008).
59. van Poelgeest MI, van Seters M, van Beurden M et al. Detection of human papillomavirus (HPV) 16-specific CD4+ T-cell immunity in patients with persistent HPV16-induced vulvar intraepithelial neoplasia in relation to clinical impact of imiquimod treatment. Clin. Cancer Res. 11(14), 5273-5280 (2005). HPV16-specific IFN-γ-associated CD4+ T-cell immunity against E2, E6 or E7 was found in 50% of VIN patients. The presence of such a pre-existing CD4+ Th1 HPV-16 T-cell response was associated with imiquimod-induced regression of lesions. (Pubitemid 41003716)
60. Welters MJ, Kenter GG, de Vos van Steenwijk PJ et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc. Natl Acad. Sci. USA 107(26), 11895-11899 (2010). Clinical response after HPV16 synthetic long peptides vaccination in HPV+ VIN 3 was associated with induction of a strong Th1 and Th2 polarized HPV-specific CD4+ T cell response. Clinical complete responders displayed distinct peak in cytokine levels after the first vaccination and HPV16-specific CD8+ T cells whereas the noncomplete responders on average displayed larger and longer existing lesions and mounted higher frequencies of HPV16-specific Tregs.
61. van der Burg SH, Melief CJ. Therapeutic vaccination against human papilloma virus induced malignancies. Curr. Opin. Immunol. 23(2), 252-257 (2011). This review excellently reviews mechanisms that determine the success and failure of therapeutic vaccination against HPVinduced malignancies and highlights the immunological setting in which these vaccines need to work.
62. Hildesheim A, Herrero R, Wacholder S et al.; Costa Rican HPV Vaccine Trial Group. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: A randomized trial. JAMA 298(7), 743-753 (2007). IgG antibodies to L1 of HPV-16/18 induced by vaccination does not accelerate clearance of the virus and should not be used to treat prevalent infections. (Pubitemid 47263157)
63. Carter JJ, Koutsky LA, Wipf GC et al. The natural history of human papillomavirus type 16 capsid antibodies among a cohort of university women. J. Infect. Dis. 174(5), 927-936 (1996). (Pubitemid 26357453)
64. Ho GY, Studentsov YY, Bierman R, Burk RD. Natural history of human papillomavirus type 16 virus-like particle antibodies in young women. Cancer Epidemiol. Biomarkers Prev. 13(1), 110-116 (2004). (Pubitemid 38116628)
65. Carter JJ, Koutsky LA, Hughes JP et al. Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J. Infect. Dis. 181(6), 1911-1919 (2000). (Pubitemid 30416152)
66. Safaeian M, Porras C, Schiffman M et al.; Costa Rican Vaccine Trial Group. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and-18 infections. J. Natl Cancer Inst. 102(21), 1653-1662 (2010).
67. Palmroth J, Namujju P, Simen-Kapeu A et al. Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes. Scand. J. Infect. Dis. 42(5), 379-384 (2010).
68. de Gruijl TD, Bontkes HJ, Walboomers JM et al. Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasia. J. Natl Cancer Inst. 89(9), 630-638 (1997). (Pubitemid 27200494)
69. Dillner J, Kjaer SK, Wheeler CM et al.; FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: Randomised controlled trial. BMJ 341, c3493 (2010).
70. Roteli-Martins C, Naud P, De Borba P et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: Up to 8.4 years of follow-up. Hum. Vaccin. Immunother. 8(3), 390-397 (2012).
71. Lehtinen M, Herrero R, Mayaud P et al. Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 24(Suppl. 3), 233-241 (2006).
72. Zumbach K, Kisseljov F, Sacharova O et al. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia. Int. J. Cancer 85(3), 313-318 (2000). (Pubitemid 30030401)
73. Viscidi RP, Sun Y, Tsuzaki B, Bosch FX, Muñoz N, Shah KV. Serologic response in human papillomavirus-associated invasive cervical cancer. Int. J. Cancer 55(5), 780-784 (1993). (Pubitemid 23354894)
74. de Gruijl TD, Bontkes HJ, Walboomers JM et al. Analysis of IgG reactivity against Human Papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: Results of a prospective study. Int. J. Cancer 68(6), 731-738 (1996).
75. Heusinkveld M, Welters MJ, van Poelgeest MI et al. The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. Int. J. Cancer 128(2), 379-389 (2011).
76. Mehta AM, Jordanova ES, van Wezel T et al. Genetic variation of antigen processing machinery components and association with cervical carcinoma. Genes. Chromosomes Cancer 46(6), 577-586 (2007). (Pubitemid 46649572)
77. Mehta AM, Jordanova ES, Corver WE et al. Single nucleotide polymorphisms in antigen processing machinery component ERAP1 significantly associate with clinical outcome in cervical carcinoma. Genes. Chromosomes Cancer 48(5), 410-418 (2009).
78. Little AM, Stern PL. Does HLA type predispose some individuals to cancer? Mol. Med. Today 5(8), 337-342 (1999). (Pubitemid 29364560)
79. Hildesheim A, Wang SS. Host and viral genetics and risk of cervical cancer: A review. Virus Res. 89(2), 229-240 (2002). (Pubitemid 35351541)
80. Bontkes HJ, Walboomers JM, Meijer CJ, Helmerhorst TJ, Stern PL. Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet 351(9097), 187-188 (1998). (Pubitemid 28037015)
81. Madeleine MM, Johnson LG, Smith AG et al. Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res. 68(9), 3532-3539 (2008).
82. Piersma SJ, Welters MJ, van der Hulst JM et al. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and-DP as a restriction element. Int. J. Cancer 122(3), 486-494 (2008). (Pubitemid 350308938)
83. de Vos van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe TH et al. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res. 70(7), 2707-2717 (2010). A large amount of tumor infiltrating T cells and found in patients with cervical cancer. These T cells seem functionally inactive within the tumor environment and may partly explain the limited efficacy of immunotherapeutic treatments.
84. Wang SS, Bratti MC, Rodríguez AC et al. Common variants in immune and DNA repair genes and risk for human papillomavirus persistence and progression to cervical cancer. J. Infect. Dis. 199(1), 20-30 (2009).
85. Zoodsma M, Nolte IM, Schipper M et al. Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int. J. Gynecol. Cancer 15(Suppl. 3), 282-290 (2005). (Pubitemid 43096595)
86. Ivansson EL, Gustavsson IM, Magnusson JJ et al. Variants of chemokine receptor 2 and interleukin 4 receptor, but not interleukin 10 or Fas ligand, increase risk of cervical cancer. Int. J. Cancer 121(11), 2451-2457 (2007). (Pubitemid 350022414)
87. Stanczuk GA, Tswana SA, Bergstrom S, Sibanda EN. Polymorphism in codons 10 and 25 of the transforming growth factor-beta 1 (TGF-beta1) gene in patients with invasive squamous cell carcinoma of the uterine cervix. Eur. J. Immunogenet. 29(5), 417-421 (2002). (Pubitemid 35177206)
88. Deshpande A, Nolan JP, White PS et al. TNF-alpha promoter polymorphisms and susceptibility to human papillomavirus 16-associated cervical cancer. J. Infect. Dis. 191(6), 969-976 (2005). (Pubitemid 40349814)
89. Gulino AV, Moratto D, Sozzani S et al. Altered leukocyte response to CXCL12 in patients with warts hypogammaglobulinemia, infections, myelokathexis (WHIM) syndrome. Blood 104(2), 444-452 (2004). (Pubitemid 38900027)
90. Bhat P, Mattarollo SR, Gosmann C, Frazer IH, Leggatt GR. Regulation of immune responses to HPV infection and during HPV-directed immunotherapy. Immunol. Rev. 239(1), 85-98 (2011).
91. van der Burg SH, Piersma SJ, de Jong A et al. Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens. Proc. Natl Acad. Sci. USA 104(29), 12087-12092 (2007). (Pubitemid 47185634)
92. Trimble CL, Peng S, Thoburn C, Kos F, Wu TC. Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. Cancer Immunol. Immunother. 59(5), 799-803 (2010). Preexisting systemic immune responses to HPV antigens which are involved in the elimination of cervix are not correlated with lesion regression.
93. Hasan UA, Bates E, Takeshita F et al. TLR9 expression and function is abolished by the cervical cancer-associated human papillomavirus type 16. J. Immunol. 178(5), 3186-3197 (2007). (Pubitemid 46333201)
94. Chang YE, Laimins LA. Microarray analysis identifies interferon-inducible genes and Stat-1 as major transcriptional targets of human papillomavirus type 31. J. Virol. 74(9), 4174-4182 (2000). (Pubitemid 30214423)
95. Zhou F, Leggatt GR, Frazer IH. Human papillomavirus 16 E7 protein inhibits interferon-γ-mediated enhancement of keratinocyte antigen processing and T-cell lysis. FEBS J. 278(6), 955-963 (2011).
96. Nees M, Geoghegan JM, Hyman T, Frank S, Miller L, Woodworth CD. Papillomavirus type 16 oncogenes downregulate expression of interferonresponsive genes and upregulate proliferation-associated and NF-kappaBresponsive genes in cervical keratinocytes. J. Virol. 75(9), 4283-4296 (2001). (Pubitemid 32410141)
97. Fausch SC, Da Silva DM, Rudolf MP, Kast WM. Human papillomavirus virus-like particles do not activate Langerhans cells: A possible immune escape mechanism used by human papillomaviruses. J. Immunol. 169(6), 3242-3249 (2002). (Pubitemid 35013171)
98. Fahey LM, Raff AB, Da Silva DM, Kast WM. A major role for the minor capsid protein of human papillomavirus type 16 in immune escape. J. Immunol. 183(10), 6151-6156 (2009).
99. Lehtinen M, Rantala I, Toivonen A et al. Depletion of Langerhans cells in cervical HPV infection is associated with replication of the virus. APMIS 101(11), 833-837 (1993). (Pubitemid 24053932)
100. Hubert P, Caberg JH, Gilles C et al. E-cadherin-dependent adhesion of dendritic and Langerhans cells to keratinocytes is defective in cervical human papillomavirusassociated (pre)neoplastic lesions. J. Pathol. 206(3), 346-355 (2005). (Pubitemid 40903199)
101. Connor JP, Ferrer K, Kane JP, Goldberg JM. Evaluation of Langerhans' cells in the cervical epithelium of women with cervical intraepithelial neoplasia. Gynecol. Oncol. 75(1), 130-135 (1999). (Pubitemid 29477815)
102. Offringa R, de Jong A, Toes RE, van der Burg SH, Melief CJ. Interplay between human papillomaviruses and dendritic cells. Curr. Top. Microbiol. Immunol. 276, 215-240 (2003). (Pubitemid 36538354)
103. de Boer MA, Jordanova ES, van Poelgeest MI et al. Circulating human papillomavirus type 16 specific T-cells are associated with HLA class I expression on tumor cells, but not related to the amount of viral oncogene transcripts. Int. J. Cancer 121(12), 2711-2715 (2007). (Pubitemid 350136416)
104. Vermeulen CF, Jordanova ES, Zomerdijk-Nooijen YA, ter Haar NT, Peters AA, Fleuren GJ. Frequent HLA class I loss is an early event in cervical carcinogenesis. Hum. Immunol. 66(11), 1167-1173 (2005).
105. Brady CS, Bartholomew JS, Burt DJ et al. Multiple mechanisms underlie HLA dysregulation in cervical cancer. Tissue Antigens 55(5), 401-411 (2000). (Pubitemid 30316150)
106. Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J. Exp. Med. 191(6), 961-976 (2000).
107. Jordanova ES, Gorter A, Ayachi O et al. Human leukocyte antigen class I, MHC class I chain-related molecule A, and CD8+/regulatory T-cell ratio: Which variable determines survival of cervical cancer patients? Clin. Cancer Res. 14(7), 2028-2035 (2008). (Pubitemid 351551112)
108. Glew SS, Duggan-Keen M, Cabrera T, Stern PL. HLA class II antigen expression in human papillomavirus-associated cervical cancer. Cancer Res. 52(14), 4009-4016 (1992).
109. Bos R, Sherman LA. CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res. 70(21), 8368-8377 (2010).
110. Torres-Aguilar H, Aguilar-Ruiz SR, González-Pérez G et al. Tolerogenic dendritic cells generated with different immunosuppressive cytokines induce antigen-specific anergy and regulatory properties in memory CD4+ T cells. J. Immunol. 184(4), 1765-1775 (2010).
111. Dong DD, Yang H, Li K et al. Human leukocyte antigen-G (HLA-G) expression in cervical lesions: Association with cancer progression, HPV 16/18 infection, and host immune response. Reprod. Sci. 17(8), 718-723 (2010).
112. Guimarães MC, Soares CP, Donadi EA et al. Low expression of human histocompatibility soluble leukocyte antigen-G (HLA-G5) in invasive cervical cancer with and without metastasis, associated with papilloma virus (HPV). J. Histochem. Cytochem. 58(5), 405-411 (2010).
113. Zhou JH, Ye F, Chen HZ, Zhou CY, Lu WG, Xie X. Altered expression of cellular membrane molecules of HLA-DR, HLA-G and CD99 in cervical intraepithelial neoplasias and invasive squamous cell carcinoma. Life Sci. 78(22), 2643-2649 (2006).
114. Gooden M, Lampen M, Jordanova ES et al. HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8? T lymphocytes. Proc. Natl Acad. Sci. USA 108(26), 10656-10661 (2011).
115. Piersma SJ, Jordanova ES, van Poelgeest MI et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res. 67(1), 354-361 (2007). (Pubitemid 46142795)
116. Del Toro-Arreola S, Arreygue-Garcia N, Aguilar-Lemarroy A et al. MHC class I-related chain A and B ligands are differentially expressed in human cervical cancer cell lines. Cancer Cell Int. 11, 15 (2011).
117. Piersma SJ, Welters MJ, van der Burg SH. Tumor-specific regulatory T cells in cancer patients. Hum. Immunol. 69(4-5), 241-249 (2008).
118. Welters MJ, Piersma SJ, van der Burg SH. T-regulatory cells in tumour-specific vaccination strategies. Expert Opin. Biol. Ther. 8(9), 1365-1379 (2008).
119. Jaafar F, Righi E, Lindstrom V et al. Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer. Am. J. Pathol. 175(4), 1525-1535 (2009).
120. Hafler DA, Kuchroo V. TIMs: Central regulators of immune responses. J. Exp. Med. 205(12), 2699-2701 (2008).
121. Peggs KS, Quezada SA, Allison JP. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy. Immunol. Rev. 224, 141-165 (2008).
122. Fourcade J, Sun Z, Benallaoua M et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207(10), 2175-2186 (2010).
123. Fourcade J, Sun Z, Pagliano O et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72(4), 887-896 (2012).
124. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 25, 267-296 (2007). (Pubitemid 46697910)
125. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8(6), 467-477 (2008). (Pubitemid 351733418)
126. Karim R, Jordanova ES, Piersma SJ et al. Tumor-expressed B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma. Clin. Cancer Res. 15(20), 6341-6347 (2009).
127. Zhu C, Anderson AC, Schubart A et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat. Immunol. 6(12), 1245-1252 (2005). (Pubitemid 43045636)
128. Liang M, Ueno M, Oomizu S et al. Galectin-9 expression links to malignant potential of cervical squamous cell carcinoma. J. Cancer Res. Clin. Oncol. 134(8), 899-907 (2008).
129. Kohrenhagen N, Volker HU, Kapp M, Dietl J, Kammerer U. Increased expression of galectin-1 during the progression of cervical neoplasia. Int. J. Gynecol. Cancer 16(6), 2018-2022 (2006). (Pubitemid 44924365)
130. Rabinovich GA, Toscano MA. Turning 'sweet' on immunity: Galectin-glycan interactions in immune tolerance and inflammation. Nat. Rev. Immunol. 9(5), 338-352 (2009).
131. Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol. Immunother. 57(7), 987-996 (2008).
132. Coles SJ, Wang EC, Man S et al. CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia. Leukemia 25(5), 792-799 (2011).
133. Gorczynski RM, Chen Z, Diao J et al. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res. Treat. 123(2), 405-415 (2010).
134. Stumpfova M, Ratner D, Desciak EB, Eliezri YD, Owens DM. The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma. Cancer Res. 70(7), 2962-2972 (2010).
135. Wang L, Liu JQ, Talebian F et al. Tumor expression of CD200 inhibits IL-10 production by tumor-associated myeloid cells and prevents tumor immune evasion of CTL therapy. Eur. J. Immunol. 40(9), 2569-2579 (2010).
136. Gorter A, Zijlmans HJ, van Gent H, Trimbos JB, Fleuren GJ, Jordanova ES. Versican expression is associated with tumor-infiltrating CD8-positive T cells and infiltration depth in cervical cancer. Mod. Pathol. 23(12), 1605-1615 (2010).
137. Trimble CL, Clark RA, Thoburn C et al. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J. Immunol. 185(11), 7107-7114 (2010).
138. Syrjänen S, Naud P, Sarian L et al. Immunosuppressive cytokine Interleukin-10 (IL-10) is up-regulated in high-grade CIN but not associated with high-risk human papillomavirus (HPV) at baseline, outcomes of HR-HPV infections or incident CIN in the LAMS cohort. Virchows Arch. 455(6), 505-515 (2009).
139. Hammes LS, Tekmal RR, Naud P et al. Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression-clinicopathological correlation. Gynecol. Oncol. 105(1), 157-165 (2007). (Pubitemid 46441454)
140. Kobayashi A, Weinberg V, Darragh T, Smith-McCune K. Evolving immunosuppressive microenvironment during human cervical carcinogenesis. Mucosal Immunol. 1(5), 412-420 (2008).
141. Munn DH, Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J. Clin. Invest. 117(5), 1147-1154 (2007). (Pubitemid 46718399)
142. Lepique AP, Daghastanli KR, Cuccovia IM, Villa LL. HPV16 tumor associated macrophages suppress antitumor T cell responses. Clin. Cancer Res. 15(13), 4391-4400 (2009).
143. Tervahauta A, Syrjänen S, Yliskoski M, Gold LI, Syrjänen K. Expression of transforming growth factor-beta 1 and-beta 2 in human papillomavirus (HPV)-associated lesions of the uterine cervix. Gynecol. Oncol. 54(3), 349-356 (1994).
144. Hazelbag S, Kenter GG, Gorter A, Fleuren GJ. Prognostic relevance of TGF-beta1 and PAI-1 in cervical cancer. Int. J. Cancer 112(6), 1020-1028 (2004). (Pubitemid 39507009)
145. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu. Rev. Immunol. 24, 99-146 (2006).
146. Nakamura T, Shima T, Saeki A et al. Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer. Cancer Sci. 98(6), 874-881 (2007). (Pubitemid 46691826)
147. Inaba T, Ino K, Kajiyama H et al. Indoleamine 2,3-dioxygenase expression predicts impaired survival of invasive cervical cancer patients treated with radical hysterectomy. Gynecol. Oncol. 117(3), 423-428 (2010).
148. Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J. Transl. Med. 9, 216 (2011).
149. Heusinkveld M, de Vos van Steenwijk PJ, Goedemans R et al. M2 macrophages induced by prostaglandin E2 and IL-6 from cervical carcinoma are switched to activated M1 macrophages by CD4+ Th1 cells. J. Immunol. 187(3), 1157-1165 (2011). Demonstrates that tumor-promoting M2 macrophages in interaction by Th1 cells can switch to M1 macrophages, which express high levels of costimulatory markers, produce high amounts of IL-12 and low amounts of IL-10, thereby stimulating a tumor-rejecting environment.
150. Ferrandina G, Lauriola L, Distefano MG et al. Increased cyclooxygenase-2 expression is associated with chemotherapy resistance and poor survival in cervical cancer patients. J. Clin. Oncol. 20(4), 973-981 (2002). (Pubitemid 34141840)
151. Gabrilovich DI, Nagaraj S. Myeloidderived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9(3), 162-174 (2009).
152. van Seters M, Beckmann I, Heijmans-Antonissen C et al. Disturbed patterns of immunocompetent cells in usual-type vulvar intraepithelial neoplasia. Cancer Res. 68(16), 6617-6622 (2008).
153. Gul N, Ganesan R, Luesley DM. Characterizing T-cell response in low-grade and high-grade vulval intraepithelial neoplasia, study of CD3, CD4 and CD8 expressions. Gynecol. Oncol. 94(1), 48-53 (2004). (Pubitemid 38950497)
154. Singh K, Yeo Y, Honest H, Ganesan R, Luesley D. Antigen processing and correlation with immunological response in vulval intraepithelial neoplasia-a study of CD1a, CD54 and LN3 expression. Gynecol. Oncol. 102(3), 489-492 (2006). (Pubitemid 44353641)
155. Abdel-Hady ES, Martin-Hirsch P, Duggan-Keen M et al. Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. Cancer Res. 61(1), 192-196 (2001). This study demonstrates that nonresponders to PDT were more likely to show HLA class I downregulation and this was associated with superficial invasion in 50% of cases. An increase in cytotoxic T-cell infiltration after PDT was on the other hand associated with clinical responses demonstrating the important role of cell mediated immunity in response to (immunotherapy) treatment. (Pubitemid 32095717)
156. Santegoets LA, van Seters M, Heijmans-Antonissen C et al. Reduced local immunity in HPV-related VIN: Expression of chemokines and involvement of immunocompetent cells. Int. J. Cancer 123(3), 616-622 (2008). (Pubitemid 351898420)
157. Guess JC, McCance DJ. Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production. J. Virol. 79(23), 14852-14862 (2005). (Pubitemid 41636283)
158. Mulvany NJ, Allen DG. Differentiated intraepithelial neoplasia of the vulva. Int. J. Gynecol. Pathol. 27(1), 125-135 (2008). (Pubitemid 351627985)
159. Terlou A, van Seters M, Kleinjan A et al. Imiquimod-induced clearance of HPV is associated with normalization of immune cell counts in usual type vulvar intraepithelial neoplasia. Int. J. Cancer 127(12), 2831-2840 (2010). Clearance of HPV after imiquimod treatment is associated with normalization in immune cell counts and p16 expression and is strongly correlated with histological regression of VIN.
160. Bourgault Villada I, Moyal Barracco M, Berville S et al. Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins. Clin. Exp. Immunol. 159(1), 45-56 (2010). Cellular responses against HPV 16 E6 and E7 responses in patients with VIN were measured and resulted in two immunodominant regions in the HPV16 E6 protein which were recognized in approximately 60% of VIN patients. They contain epitopic peptides able to bind to different HLA class I and II molecules.
161. Baldwin PJ, van der Burg SH, Boswell CM et al. Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. Clin. Cancer Res. 9(14), 5205-5213 (2003). (Pubitemid 37413570)
162. Todd RW, Roberts S, Mann CH, Luesley DM, Gallimore PH, Steele JC. Human papillomavirus (HPV) type 16-specific CD8+ T cell responses in women with high grade vulvar intraepithelial neoplasia. Int. J. Cancer 108(6), 857-862 (2004). (Pubitemid 38112614)
163. Davidson EJ, Sehr P, Faulkner RL et al. Human papillomavirus type 16 E2-and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia. J. Gen. Virol. 84(Pt 8), 2089-2097 (2003). (Pubitemid 36927238)
164. Davidson EJ, Boswell CM, Sehr P et al. Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. Cancer Res. 63(18), 6032-6041 (2003). (Pubitemid 37187507)
165. Davidson EJ, Faulkner RL, Sehr P et al. Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). Vaccine 22(21-22), 2722-2729 (2004). (Pubitemid 38900647)
166. Smyth LJ, Van Poelgeest MI, Davidson EJ et al. Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination. Clin. Cancer Res. 10(9), 2954-2961 (2004). (Pubitemid 38619670)
167. Hildesheim A, Han CL, Brinton LA, Kurman RJ, Schiller JT. Human papillomavirus type 16 and risk of preinvasive and invasive vulvar cancer: Results from a seroepidemiological case-control study. Obstet. Gynecol. 90(5), 748-754 (1997). (Pubitemid 27449727)
168. Nofech-Mozes S, Kupets R, Rasty G, Ismiil N, Covens A, Khalifa MA. Cyclooxygenase-2 (COX-2) immunostaining does not correlate with the degree of vulvar neoplasia. J. Obstet. Gynaecol. Can. 28(4), 290-294 (2006).
169. Davidson EJ, Davidson JA, Sterling JC, Baldwin PJ, Kitchener HC, Stern PL. Association between human leukocyte antigen polymorphism and human papillomavirus 16-positive vulval intraepithelial neoplasia in British women. Cancer Res. 63(2), 400-403 (2003). (Pubitemid 36152499)
170. Kohrenhagen N, Voelker HU, Kapp M, Dietl J, Kämmerer U. The expression of galectin-1 in vulvar neoplasia. Anticancer Res. 30(5), 1547-1552 (2010).
171. Brustmann H. Galectin-3 and CD1apositive dendritic cells are involved in the development of an invasive phenotype in vulvar squamous lesions. Int. J. Gynecol. Pathol. 25(1), 30-37 (2006). (Pubitemid 44638332)
172. van der Burg SH, Arens R, Melief CJ. Immunotherapy for persistent viral infections and associated disease. Trends Immunol. 32(3), 97-103 (2011).
173. Spirtos NM, Smith LH, Teng NN. Prospective randomized trial of topical alpha-interferon (alpha-interferon gels) for the treatment of vulvar intraepithelial neoplasia III. Gynecol. Oncol. 37(1), 34-38 (1990). (Pubitemid 20147966)
174. Pepas L, Kaushik S, Bryant A, Nordin A, Dickinson HO. Medical interventions for high grade vulval intraepithelial neoplasia. Cochrane Database Syst. Rev. 4, CD007924 (2011).
175. Belardelli F, Gresser I. The neglected role of type I interferon in the T-cell response: Implications for its clinical use. Immunol. Today 17(8), 369-372 (1996). (Pubitemid 26247796)
176. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13(2), 119-134 (2002). (Pubitemid 34229387)
177. Fried MW, Shiffman ML, Reddy KR et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 347(13), 975-982 (2002).
178. Bilu D, Sauder DN. Imiquimod: Modes of action. Br. J. Dermatol. 149(Suppl. 66), 5-8 (2003). (Pubitemid 38064505)
179. Schön MP, Schön M. Immune modulation and apoptosis induction: Two sides of the antitumoral activity of imiquimod. Apoptosis 9(3), 291-298 (2004). (Pubitemid 38986952)
180. Iavazzo C, Pitsouni E, Athanasiou S, Falagas ME. Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia. Int. J. Gynaecol. Obstet. 101(1), 3-10 (2008).
181. Terlou A, Kleinjan A, Beckmann I et al. Nonsteroidal anti-inflammatory drugs do not interfere with imiquimod treatment for usual type vulvar intraepithelial neoplasia. Int. J. Cancer 128(10), 2463-2469 (2011).
182. Fehr MK, Hornung R, Schwarz VA, Simeon R, Haller U, Wyss P. Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5-aminolevulinic acid. Gynecol. Oncol. 80(1), 62-66 (2001). (Pubitemid 32062090)
183. Korbelik M. Induction of tumor immunity by photodynamic therapy. J. Clin. Laser Med. Surg. 14(5), 329-334 (1996). (Pubitemid 26405725)
184. Mroz P, Hashmi JT, Huang YY, Lange N, Hamblin MR. Stimulation of anti-tumor immunity by photodynamic therapy. Expert Rev. Clin. Immunol. 7(1), 75-91 (2011).
185. Frost GA, Halliday GM, Damian DL. Photodynamic therapy-induced immunosuppression in humans is prevented by reducing the rate of light delivery. J. Invest. Dermatol. 131(4), 962-968 (2011).
186. Daayana S, Winters U, Stern PL, Kitchener HC. Clinical and immunological response to photodynamic therapy in the treatment of vulval intraepithelial neoplasia. Photochem. Photobiol. Sci. 10(5), 802-809 (2011).
187. Hillemanns P, Untch M, Dannecker C et al. Photodynamic therapy of vulvar intraepithelial neoplasia using 5-aminolevulinic acid. Int. J. Cancer 85(5), 649-653 (2000). (Pubitemid 30080477)
188. Melief CJ, van der Burg SH. Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines. Nat. Rev. Cancer 8(5), 351-360 (2008). (Pubitemid 351589701)
189. Fiander AN, Tristram AJ, Davidson EJ et al. Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: Clinical results from a multicenter Phase II trial. Int. J. Gynecol. Cancer 16(3), 1075-1081 (2006). (Pubitemid 43886729)
190. Kenter GG, Welters MJ, Valentijn AR et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin. Cancer Res. 14(1), 169-177 (2008). (Pubitemid 351377993)
191. Welters MJ, Kenter GG, Piersma SJ et al. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine. Clin. Cancer Res. 14(1), 178-187 (2008). (Pubitemid 351377994)
192. Shackleton M, Davis ID, Hopkins W et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun. 4, 9 (2004).
193. Oldenhove G, de Heusch M, Urbain-Vansanten G et al. CD4+ CD25+ regulatory T cells control T helper cell type 1 responses to foreign antigens induced by mature dendritic cells in vivo. J. Exp. Med. 198(2), 259-266 (2003). (Pubitemid 36987851)
194. Nakanishi Y, Lu B, Gerard C, Iwasaki A. CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462(7272), 510-513 (2009).
195. Vermeij R, Leffers N, Hoogeboom BN et al. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm Phase II study. Int. J. Cancer 131(5), E670-E678 (2011).
196. Gannagé M, Buzyn A, Bogiatzi SI et al. Induction of NKG2D ligands by gamma radiation and tumor necrosis factor-alpha may participate in the tissue damage during acute graft-versus-host disease. Transplantation 85(6), 911-915 (2008). (Pubitemid 351440760)